Relationship between high-sensitivity c-reactive protein and risk factors in patients with peripheral arterial disease - A cross-sectional study

Angiology

Volumn 64, Issue 3, 2013, Pages 230-236

  Maksimovic, Milos ^a   Vlajinac, Hristina ^a   Radak, Djordje ^a   Marinkovic, Jelena ^a   Jorga, Jagoda ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

high sensitivity C reactive protein; peripheral arterial disease; risk factors

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; HIGH SENSITIVITY C REACTIVE PROTEIN; UNCLASSIFIED DRUG; URIC ACID;

ABDOMINAL OBESITY; ADULT; ANKLE BRACHIAL INDEX; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE SEVERITY; FEMALE; FIBRINOGEN BLOOD LEVEL; GANGRENE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN BLOOD LEVEL; RISK FACTOR; URIC ACID BLOOD LEVEL;

AGED; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE;

EID: 84876000721     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319712440303     Document Type: Article

References (56)

1. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997 ; 336 (14). 973-979
2. Cao JJ, Thach C, Manolio TA, et al. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation. 2003 ; 108 (2). 166-170
3. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998 ; 97 (5). 425-428
4. Rossi E, Biasucci LM, Citterio F, Pelliccioni S, Monaco C, Ginntetti F. Risk of myocardial infection and angina in patients with severe peripheral arterial disease: predictive role of C-reactive protein. Circulation. 2002 ; 105 (7). 800-803
5. Silvestro A, Scopacasa F, Ruocco A, et al. Inflammatory status and endothelial function in asymptomatic and symptomatic peripheral arterial disease. Vasc Med. 2003 ; 8 (4). 225-232
6. Shankar A, Li J, Nieto JF, Klein BE, Klein R, et al. Association between C- reactive protein level and peripheral arterial disease among US adults without cardiovascular disease, diabetes, or hypertension. Am Heart J. 2007 ; 154 (3). 495-501
7. Tillett WS, Frances T. Serological reactions in pneumonia with a non-protein fraction of pneumococcus. J Exp Med. 1930 ; 52 (4). 561-571
8. Ballou SP, Kushner I. C-reactive protein and the acute phase response. Adv Int Med. 1992 ; 37: 313-336
9. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention [review]. Circulation. 2003 ; 107 (3). 363-369
10. Vainas T, Stassen FR, de Graaf R, et al. C-reactive protein in peripheral arterial disease: relation to severity of the disease and to future cardiovascular events. J Vasc Surg. 2005 ; 42 (2). 243-251
11. Ridker PM, Hennekens CH, Buring JE, Rifai N, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000 ; 342 (12). 836-843
12. Greenland P, Abrams J, Aurigemma GP, et al. Prevention Conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerosis burden: Writing Group III. Circulation. 2000 ; 101: e16 - e22
13. Criqui MH, Fonek A, Klauber MR, Barrett-Connor E, Gabriel S, et al. The sensitivity, specificity, and predictive value of traditional clinical evaluation of peripheral arterial disease: results from noninvasive testing in a defined population. Circulation. 1985 ; 71 (3). 515-522
14. Aronow WS. Management of peripheral arterial disease of the lower extremities in elderly patients. J Gerontol. 2004 ; 59A (2). 172-177
15. Obesity: Preventing and Managing the Global Epidemic. Geneva, Switzerland: WHO ; 1998 :
16. Durnin JVGA, Womersley J. Body fat assessed from total body density and its estimation from skin fold thickness; measurements on 481 men and women aged from 16 to 72 years. Br J Nutr. 1974 ; 32 (1). 77-97
17. Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 ; 42: 1206-1252
18. Pearson TA, Mensah GA, Alexander RW. for the Centers for Disease Control and Prevention and the American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003 ; 107(3): 499-511
19. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005 ; 112 (17). 2735-2752
20. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961 ; 4 (4). 561-571
21. Beck AT, Steer RA, Garbin MG. Psychometric properties of the beck depression inventory: twenty-five years of evaluation. Clin Psychol Rev. 1988 ; 8 (1). 77-100
22. Baecke JA, Burema HJ, Fritjers JER. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr. 1982 ; 36 (5). 932-942
23. Abdellaoui A, Al-Khaffaf H. C-reactive protein (CRP) as a marker in peripheral vascular disease. Eur J Vasc Endovasc Surg. 2007 ; 34 (1). 18-22
24. Vu JD, Vu JB, Pio JR, et al. Impact of C-reactive protein on the likelihood of peripheral arterial disease in United States adults with the metabolic syndrome, Diabetes Mellitus, and pre-existing cardiovascular disease. Am J Cardiol. 2005 ; 96 (5). 655-658
25. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systematic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. J Am Med Assoc. 2001 ; 285 (19). 2481-2485
26. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002 ; 347 (20). 1557-1565
27. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GDO, Fowkes FGR. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh artery study. Circulation. 2005 ; 112 (7). 976-983
28. McDermott MM, Green D, Greenland P, et al. Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index. Am J Cardiol. 2003 ; 92 (2). 194-199
29. McDermott MM, Guralnik JM, Greenland P, et al. Inflammatory and thrombotic blood markers and walking-related disability in men and women with and without peripheral arterial disease. J Am Geriatr Soc. 2004 ; 52 (11). 1888-1894
30. Beckman JA, Preis O, Ridker PM, Gerhard-Herman M. Comparison of usefulness of inflammatory markers in patients with versus without peripheral arterial disease in predicting adverse cardiovascular outcomes (myocardial infarction, stroke, and death). Am J Cardiol. 2005 ; 96 (10). 1374-1378
31. Vainas T, Lubbers T, Stassen FR, et al. Serum C-reactive protein level is associated with abdominal aortic aneurysm size and may be produced by aneurismal tissue. Circulation. 2003 ; 107 (8). 1103-1105
32. Hozawa A, Ohmori K, Kyriyama S, et al. C-reactive protein and peripheral artery disease among Japanese elderly: the Tsurugaya Project. Hypertens Res. 2004 ; 27 (12). 955-961
33. Daskalopoulou SS, Pathmarajah M, Kakkos SK, et al. Association between ankle-brachial index and risk factor profile in patients newly diagnosed with intermittent claudication. Circ J. 2008 ; 72 (3). 441-448
34. Meru AV, Mittra S, Thyagarajan B, Chugh A. Intermittent claudication: an overview. Atherosclerosis. 2006 ; 187: 221-237
35. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA. 2006 ; 295 (5). 547-553
36. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol. 2006 ; 47: 921-929
37. Nakou ES, Liberopoulos EN, Milionis HJ, Elisaf MS. The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview. Curr Vasc Pharmacol. 2008 ; 6 (4). 258-270
38. Tennent GA, Hutchinson WL, Kahan MC, et al. Transgenic human CRP is not pro-atherogenic, in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A. 2005 ; 102: 8309-8314
39. Pitsavos C, Panagiotakos DB, Tzima N, et al. Diet, exercise and C-reactive protein levels in people with abdominal obesity: the ATTICA epidemiological study. Angiology. 2007 ; 58 (2). 225-233
40. Paraskevas KI, Bessias N, Papas TT, Andrikopoulos V, Mikhailidis DP. Is high sensitivity C-reactive protein associated with peripheral atherosclerosis. Angiolog. 200 ; ;6 (0(1). 8-1
41. Wattanakit K, Folsom AR, Selvin E, et al. Risk factors for peripheral arterial disease incidence in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis. 2005 ; 180 (2). 389-397
42. Johnson BD, Kip KE, Marroquin OC, et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation. 2004 ; 109 (6). 726-732
43. McDermott MM, Guralnik JM, Corsi A, et al. Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study. Am Heart J. 2005 ; 150 (2). 276-281
44. Owens CD, Ridker PM, Belkin M, et al. Elevated C-reactive protein levels are associated with postoperative events in patients undergoing lower extremity vein bypass surgery. J Vasc Surg. 2007 ; 45 (1). 2-9
45. Doweik L, Maca T, Schillinger M, Budinsky A, Sabeti S, Minar E. Fibrinogen predicts mortality in high risk patients with peripheral artery disease. Eur J Vasc Endovasc Surg. 2003 ; 26 (4). 381-386
46. Koenig W.. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost. 2003 ; 89 (4). 601-609
47. Gagliardi AC, Miname MH, Santos RD. Uric acid: a marker of increased cardiovascular risk. Atherosclerosis. 2009 ; 202 (1). 11-17
48. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol. 2005 ; 25 (1). 39-42
49. Santos AC, Lopes C, Guimarães JT, Barros H. Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome. Int J Obes (Lond). 2005 ; 29 (12). 1452-1456
50. Festa A, D'Agostino R, Howard Jr, Mykkanene L, Tracy R, Haffner S. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000 ; 102 (1). 42-47
51. Liu ZM, Ho SC. The association of serum C-reactive protein, uric acid and magnesium with insulin resistance in Chinese postmenopausal women with prediabetes or early untreated diabetes. Maturitas. 2011 ; 70 (2). 176-181
52. Lin SD, Tsai DH, Hsu SR. Association between serum uric acid level and components of the metabolic syndrome. J Chin Med Assoc. 2006 ; 69 (11). 512-516
53. Lemieux I, Pascot A, Prud'homme D, et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol. 2001 ; 21 (6). 961-967
54. Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev. 2002 ; 3 (2). 85-101
55. Schillinger M, Exner M, Mlekusch W, et al. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J. 2004 ; 25 (9). 742-748
56. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant. 2007 ; 22 (1). 118-127